NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (1) See Note 1 for a description of the segments in which the Company operates. (2) Export sales are not significant. In 2010, 2009 and 2008, the Company did not have a customer that represented 10% of total revenues. (3) Amounts not allocated to segments include interest (income) expense, non-controlling interests and general corporate (income) expense. (4) General corporate includes cash and marketable securities. (5) Includes $966 million of net litigation gain, comprised of a $333 million expense in the Pharmaceutical segment and a gain of $1,299 million in the Medical Devices and Diagnostics segment. Includes $569 million of product liability expense, comprised of $114 million in the Pharmaceutical segment and $455 million in the Medical Devices and Diagnostics segment. The Medical Devices and Diagnostics segment also includes $280 million expense for the cost associated with the DePuy ASR™ Hip recall program. (6) Includes $1,186 million of restructuring expense, comprised of $369 million, $496 million, and $321 million for the Consumer, Pharmaceutical, and Medical Devices and Diagnostics segments, respectively. Includes $386 million of fourth quarter net litigation gain, comprised of a $92 million expense in the Pharmaceutical segment and a gain of $478 million in the Medical Devices and Diagnostics segment. (7) Includes $7 million and $174 million of IPR&D for the Consumer and Medical Devices and Diagnostics segments, respectively. Includes $379 million of fourth quarter net litigation gain, comprised of a $50 million expense in the Consumer segment and a gain of $429 million in the Medical Devices and Diagnostics segment. The Medical Devices and Diagnostics segment also includes a $536 million gain on the divestiture of the Professional Wound Care business of Ethicon, Inc. (8) Long-lived assets include property, plant and equipment, net for 2010, 2009 and 2008 of $14,553, $14,759 and $14,365, respectively, and intangible assets and goodwill, net for 2010, 2009 and 2008 of $32,010, $31,185 and $27,695, respectively. Sales to Customers (2) __________________________________________ (Dollars in Millions) 2010 2009 2008 Consumer — United States $ 5,519 6,837 6,937 International 9,071 8,966 9,117 Total 14,590 15,803 16,054 Pharmaceutical — United States 12,519 13,041 14,831 International 9,877 9,479 9,736 Total 22,396 22,520 24,567 Medical Devices and Diagnostics — United States 11,412 11,011 10,541 International 13,189 12,563 12,585 Total 24,601 23,574 23,126 Worldwide total $61,587 61,897 63,747 Operating Profit Identifiable Assets __________________________________________ __________________________________________ (Dollars in Millions) 2010 (5) 2009 (6) 2008 (7) 2010 2009 2008 Consumer $ 2,342 2,475 2,674 $ 23,753 24,671 23,765 Pharmaceutical 7,086 6,413 7,605 19,961 21,460 19,544 Medical Devices and Diagnostics 8,272 7,694 7,223 23,277 22,853 20,779 Total 17,700 16,582 17,502 66,991 68,984 64,088 Less: Expense not allocated to segments (3) 753 827 573 General corporate (4) 35,917 25,698 20,824 Worldwide total $16,947 15,755 16,929 $102,908 94,682 84,912 Additions to Property, Depreciation and Plant & Equipment Amortization __________________________________________ __________________________________________ (Dollars in Millions) 2010 2009 2008 2010 2009 2008 Consumer $ 526 439 499 $ 532 513 489 Pharmaceutical 508 535 920 912 922 986 Medical Devices and Diagnostics 1,113 1,114 1,251 1,270 1,124 1,146 Segments total 2,147 2,088 2,670 2,714 2,559 2,621 General corporate 237 277 396 225 215 211 Worldwide total $2,384 2,365 3,066 $2,939 2,774 2,832 Sales to Customers (2) Long-Lived Assets (8) __________________________________________ __________________________________________ (Dollars in Millions) 2010 2009 2008 2010 2009 2008 United States $29,450 30,889 32,309 $ 23,315 22,399 21,674 Europe 15,510 15,934 16,782 16,791 17,347 14,375 Western Hemisphere excluding U.S. 5,550 5,156 5,173 3,653 3,540 3,328 Asia-Pacific, Africa 11,077 9,918 9,483 2,089 1,868 1,898 Segments total 61,587 61,897 63,747 45,848 45,154 41,275 General corporate 715 790 785 Other non long-lived assets 56,345 48,738 42,852 Worldwide total $61,587 61,897 63,747 $102,908 94,682 84,912 18. Segments of Business (1) and Geographic Areas 61